What is the level of liabilities of AB Science this year?
AB Science has a debt balance of 46.51 M EUR this year.
AB Science Liabilities 2024
AB Science Liabilities
46.51 M EUR
Ticker
AB.PA
ISIN
FR0010557264
WKN
A1CXBG
In 2024, AB Science's total liabilities amounted to 46.51 M EUR, a -21.85% difference from the 59.51 M EUR total liabilities in the previous year.
AB Science Aktienanalyse
What does AB Science do?
AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry. AB Science ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing AB Science's Liabilities
AB Science's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AB Science's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing AB Science's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
AB Science's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in AB Science’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about AB Science stock
What were the liabilities of AB Science compared to the previous year?
The liabilities of AB Science have increased by -21.85% dropped compared to the previous year.
What are the consequences of high debt for investors of AB Science?
High liabilities can pose a risk for investors of AB Science, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in AB Science?
Low liabilities mean that AB Science has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of AB Science affect the company?
An increase in liabilities of AB Science can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of AB Science affect the company?
A decrease in the liabilities of AB Science can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of AB Science?
Some factors that can influence the liabilities of AB Science include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of AB Science so important for investors?
The liabilities of AB Science are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can AB Science take to modify the liabilities?
To change its liabilities, AB Science can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does AB Science pay?
Over the past 12 months, AB Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AB Science is expected to pay a dividend of 0 EUR.
What is the dividend yield of AB Science?
The current dividend yield of AB Science is .
When does AB Science pay dividends?
AB Science pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AB Science?
AB Science paid dividends every year for the past 0 years.
What is the dividend of AB Science?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is AB Science located?
AB Science is assigned to the 'Health' sector.
Wann musste ich die Aktien von AB Science kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AB Science from 10/5/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
When did AB Science pay the last dividend?
The last dividend was paid out on 10/5/2024.
What was the dividend of AB Science in the year 2023?
In the year 2023, AB Science distributed 0 EUR as dividends.
In which currency does AB Science pay out the dividend?
The dividends of AB Science are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AB Science stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von AB Science
Our stock analysis for AB Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AB Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
